iPS Cells,
To be the heart of
animal regenerative medicine.
Firstly with dogs.

We want to save as many animal lives as possible.
In order to fulfill such goal, we apply regenerative medicine that is now being put to practical use in humans to animals.
For this purpose, we utilize our proprietary animal iPS cell technology that enables us to deliver high-quality regenerative medicine unlike relying on living animal donors. Hence, we hope iPS cells to be the heart of animal regenerative medicine.

We started development of iPS cells-derived regenerative medicine products, firstly with dogs.

And, safety is the first and foremost important thing for bringing regenerative medicine to animals.
We also value the security of veterinarians and people whose partner animals are treated.
We grow this technology in the same way as we hold the passion to nurture our dogs, cats, and other precious partner animals, and aim our goal that is to create a society in which both people and animals can live happily.

Learn more about iPS cells and animal regenerative medicine


枝村一弥(獣医師)Kazuya Edamura

Kazuya Edamura
DVM Ph. D.

External Director CSO and co-founder
Professor, Laboratory of Veterinary Surgery Department of Veterinary Medicine College of Bioresource and Sciences Nihon University
Vice President, Japanese Society of Veterinary Regenerative Medicine (JSVRM)
Vice President, Consortium for the Promotion of Animal Regenerative Medicine (CARM)

枝村一弥(獣医師)Kazuya Edamura

Contributing to animal health and family happiness with iPS cells.

Today, In Japan, many dogs and cats live in households, and their numbers continue to outnumber the population of children under the age of 15. Dogs and cats are treated with more care than ever before, and have become important members of the family as "companion animals". With that background, expectations for veterinary medicine are growing. In fact, with the development of veterinary medicine, dogs and cats are now able to receive advanced treatments similar to those available to humans, and the life expectancy of dogs and cats have increased over the years. Unfortunately, some diseases are difficult to cure even with existing therapies. Therefore, there are high expectations for regenerative medicine in veterinary field.
In recent years, the clinical application of induced pluripotent stem cells (iPS cells) has begun in human medicine, and true regenerative medicine is now being developed. However, no iPS cells have been established for clinical use in dogs and cats, which has been one of the difficulties to implementing regenerative medicine. And, for the first time in the world, we succeeded in producing iPS cells that can be clinically applied in veterinary medicine.

The animal iPS cells we have established can be used not only for the treatment of intractable diseases, but also for the pathological analysis of various diseases and the development of animal drugs. Thus, we are confident that our iPS cells can make a significant contribution to the maintenance of animal health. And through this, we hope to make the families that live with animals happy and provide an environment where they can have a better environment with their animals.


Taking Animal Regenerative Medicine to the Next Stage
with Unique iPS Cell-Derived Products.

Animals such as dogs, has been said to be more difficult to create iPS cells than in mice, rats, or humans due to pluripotency induction resistance. In this context, Professor Kazuya Edamura of Nihon University, Associate Professor Seiji Shiozawa of Kurume University, and Professor Hideyuki Okano of Keio University have perfected a unique technology for the establishment of canine iPS cells. This unique technology does not require any physical burden on the donor animal and does not require any lead time (preparation period) for cell preparation prior to treatment, and is expected to enable the supply of cell therapy products with consistent quality of stability. Utilizing this proprietary technology that can take animal regenerative medicine to the next stage, Vetanic is able to advance research and development of various regenerative medicine products such as iPS cell-derived canine mesenchymal stem cells (MSCs); and has applied to the Ministry of Agriculture, Forestry and Fisheries for approval of manufacturing and marketing regenerative medicine products for veterinary use under the Pharmaceutical and Food Safety Act, with the hope of commercializing them.